Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

51.66
Delayed Data
As of May 27
 +0.07 / +0.14%
Today’s Change
49.51
Today|||52-Week Range
72.31
-21.30%
Year-to-Date
Endo Could Be the Next Activist Target in Generics
2:03pm / TheStreet.com - Paid Partner Content
Allergan to do Smaller Deals and Boost Credit Rating
May 23 / TheStreet.com - Paid Partner Content
Stocks Near 5-Week Lows
May 26 / GuruFocus News - Paid Partner Content
AstraZeneca's Severe Asthma Drug Positive in Phase III
May 18 / Zacks.com - Paid Partner Content
Billionaires are Dumping These 3 Stocks
May 25 / MotleyFool.com - Paid Partner Content
5 Stocks We're Never Selling
May 14 / MotleyFool.com - Paid Partner Content
Is This the Perfect Time to Buy Teva?
May 24 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close51.59
Today’s open51.82
Day’s range51.56 - 52.45
Volume3,708,955
Average volume (3 months)6,183,698
Market cap$52.8B
Dividend yield2.63%
Data as of 4:02pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-48.06%
Earnings growth (this year)-3.08%
Earnings growth (next 5 years)+7.20%
Revenue growth (last year)-3.25%
P/E ratio26.8
Price/Sales2.89
Price/Book1.77

Competitors

 Today’s
change
Today’s
% change
DEPODepomed Inc+0.33+1.65%
BGNEBeiGene Ltd-0.32-1.16%
DNAIProNAi Therapeutics ...-0.58-9.06%
OASMOasmia Pharmaceutica...-0.03-0.64%
Data as of 3:59pm ET, 05/27/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$1.18
Annual revenue (last year)$19.6B
Annual profit (last year)$1.6B
Net profit margin8.09%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
Erez Vigodman
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Tel Aviv

Forecasts

Partner Offers

Search for Jobs